gefitinib has been researched along with Adenocystic Carcinoma in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Blumenschein, GR; El-Naggar, AK; Glisson, BS; Gonzalez-Angulo, AM; Jakob, JA; Kies, MS; Kupferman, ME; Lee, JJ; Liu, DD | 1 |
| Fujita, M; Hirano, R; Hirota, T; Kubo, A; Matsumoto, T; Nabeshima, K; Uchino, J; Watanabe, K; Yamaguchi, E; Yokoi, T | 1 |
| Dahse, R; Kosmehl, H | 1 |
| Cai, Y; Chen, G; Jia, J; Liu, B; Liu, H; Liu, JY; Zhang, JL; Zhang, W; Zhao, YF; Zhong, HY | 1 |
1 trial(s) available for gefitinib and Adenocystic Carcinoma
| Article | Year |
|---|---|
Phase II study of gefitinib in patients with advanced salivary gland cancers.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Carcinoma, Adenoid Cystic; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Gefitinib; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Quinazolines; Remission Induction; Salivary Gland Neoplasms; Survival Analysis; Treatment Outcome | 2015 |
3 other study(ies) available for gefitinib and Adenocystic Carcinoma
| Article | Year |
|---|---|
Adenoid Cystic Carcinoma of the Lung with an EGFR Mutation.
Topics: Aged, 80 and over; Antineoplastic Agents; Carcinoma, Adenoid Cystic; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Quinazolines; Taxoids | 2016 |
Detection of drug-sensitizing EGFR exon 19 deletion mutations in salivary gland carcinoma.
Topics: Aged; Carcinoma, Adenoid Cystic; Carcinoma, Mucoepidermoid; DNA, Neoplasm; Drug Resistance; ErbB Receptors; Erlotinib Hydrochloride; Exons; Female; Gefitinib; Humans; Male; Middle Aged; Mutation; Parotid Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2008 |
Epithelial mesenchymal transition is required for acquisition of anoikis resistance and metastatic potential in adenoid cystic carcinoma.
Topics: Animals; Anoikis; Antineoplastic Agents; Apoptosis; Carcinoma, Adenoid Cystic; Cell Line, Tumor; Cell Movement; Epithelial-Mesenchymal Transition; ErbB Receptors; Female; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Neoplasm Metastasis; Neoplasm Transplantation; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; Salivary Gland Neoplasms; Snail Family Transcription Factors; Transcription Factors | 2012 |